Improving Adherence to Home Blood Pressure Monitoring With Pharmacist Support
NCT ID: NCT04577131
Last Updated: 2021-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1 participants
INTERVENTIONAL
2020-11-05
2020-11-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Do Home Monitors Improve Blood Pressure Control?
NCT01579136
A Home-based Blood Pressure Monitoring Program to Promote Better Management of Hypertension
NCT01525108
Home Blood Pressure in Hypertension Management
NCT00841308
Home Blood Pressure Telemonitoring and Case Management to Control Hypertension
NCT00781365
Electronic Communications and Home Blood Pressure Monitoring
NCT00158639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As part of their usual blood pressure monitoring, participants will be given an Omron 3 series or 5 series blood pressure monitor which has been cleared by the US Food and Drug Administration and validated to meet accuracy and performance requirements. For one month, participants will monitor their blood pressure once a day and then return the device to the clinic at the end of the study. Participants will text their blood pressure result to the American Heart Association's Check, Change, Control (CCC) secure online tracker.
As part of the research study, participants will also be randomized to either receive or not receive weekly check-in phone calls from a pharmacist to review their blood pressures and the number of times they tested in that week. Approximately 50 individuals will participate in this study. Participation in this study will last 1 month.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With check-ins
Daily blood pressure monitoring with weekly check-ins
Weekly check-in
Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
Without check-ins
Daily blood pressure monitoring without weekly check-ins
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Weekly check-in
Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Uncontrolled hypertension (BP \> 130/80 mm Hg)
Exclusion Criteria
* patients without a mobile phone or texting capability
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Virginia Commonwealth University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dave Dixon, PharmD
Role: PRINCIPAL_INVESTIGATOR
Virginia Commonwealth University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Commonwealth University
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM20019041
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.